Skip to main content

Bausch Health Companies Inc. Value Stock - Dividend - Research Selection

Bausch health

ISIN: CA0717341071 , WKN: A2JQ1X

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company is engaged in the development and commercialization of a range of generics, generic and branded products, over-the-counter (OTC) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgery devices and aesthetic devices). It operates through two segments: developed markets and emerging markets. The Developed Markets segment focuses on the areas of dermatology, neurology, gastrointestinal diseases and ophthalmology. The Emerging Markets segment focuses primarily on branded generics, OTC products and medical devices. The pharmaceutical products include Xifaxan, Solodyn and Glumetza. OTC products include Preservision, Biotrue and Boston. Other generics include latanoprost and metronidazole. The ophthalmic products include intraocular lenses such as Akreos, enVista, Crystalens and Trulign.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Bausch Health: Repricing Continues As Deleveraging Gains Traction

2025-09-11
Bausch Health shows stable cash generation and operational momentum. Read more on the BHC stock's Buy rating and how it offers upside potential despite debt risks.

Tracking Carl Icahn's 13F Report - Q2 2025 Update

2025-09-07
Icahn’s Q2 2025 13F shows a portfolio trimmed to 12 holdings, with top positions in IEP, CVI, SWX, UAN, and IFF. Click here to read more about the portfolio.

Why Bausch Health Stock Surged By Nearly 20%

2025-08-12

Bausch Health Companies Inc. 2025 Q2 - Results - Earnings Call Presentation

2025-07-30
The following slide deck was published by Bausch Health Companies Inc.

Bausch Health Companies Inc. (BHC) Q2 2025 Earnings Call Transcript

2025-07-30
Bausch Health Companies Inc. (NYSE:BHC) Q2 2025 Earnings Conference Call July 30, 2025 5:00 PM ETCompany ParticipantsGaren Sarafian - VP & Head of...

Bausch Health's Xifaxan Patent Clarity, Policy Commentary in Focus for Q2, RBC Says

2025-07-15
Bausch Health's (BHC) potential updates on the patent infringement case regarding the Xifaxan drug a

Bausch Health Companies (BHC) Canada Announces Expanded Availability of CABTREO Gel

2025-07-11
Bausch Health Companies Inc. (NYSE:BHC) is one of the 13 Best Healthcare Stocks to Buy Under $10. On July 9, Bausch Health Companies Inc. (NYSE:BHC), Canada, announced the availability of CABTREO gel 1.2% w/w, 0.15% w/w, and 3.1% w/w to beneficiaries of the public drug plans of Nova Scotia and Ontario. The gel, which treats acne vulgaris, […]

Chlamydia Market Analysis and Forecast, 2025-2035 Featuring ActivBiotics, Bausch Health, Allergan, WCG Clinical, Hologic, Evofem, CRMI, Meridian Bioscience, Pfizer

2025-07-11
The global chlamydia market is projected for significant growth driven by rising chlamydia infections, with 127 million new cases annually, as per the World Health Organization. Key factors boosting the market include the adoption of advanced diagnostics like Nucleic Acid Amplification Tests (NAATs) and Point-of-Care Testing (POCT), alongside public health initiatives increasing awareness and screening. Challenges such as asymptomatic cases, social stigma, and antibiotic resistance persist, but

CORRECTING and REPLACING: Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Nova Scotia and Two Federal Programs

2025-07-10
This press release updates the headline of the previously posted release LAVAL, QC / ACCESS Newswire / July 10, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that PrCABTREOTM (clindamycin ...

Bausch Health Appoints New Chief Accounting Officer

2025-07-10
LAVAL, QC / ACCESS Newswire / July 10, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced the appointment of Steven Lee as Senior Vice President, Controller and Chief Accounting Officer, ...